Transplantation Immunology

Historical Context & Motivation

The dream of replacing a failing organ with a healthy one is ancient, but the immunological barriers to transplantation were not appreciated until the twentieth century. Early attempts at skin grafting between unrelated individuals invariably failed, and the biological basis for this failure remained mysterious until the discovery of the major histocompatibility complex (MHC). Understanding transplantation immunology is not merely an academic exercise — it directly informs how clinicians select donors, choose immunosuppressive regimens, and monitor graft survival. For USMLE Step 1, this topic integrates concepts from adaptive immunity, antigen presentation, and pharmacology into a single high-yield clinical framework.

The central question driving this field remains: How does the recipient's immune system recognize a transplanted organ as foreign, and how can we prevent or control that destructive response while preserving protective immunity? Answering this requires a thorough understanding of MHC genetics, allorecognition pathways, and the mechanisms of both acute and chronic rejection.

Core Principles & Definitions

Transplantation immunology rests on several foundational concepts that connect MHC biology to clinical outcomes. The allograft — a graft between genetically non-identical members of the same species — is the most clinically relevant transplant type. The immune response against an allograft is primarily driven by T-cell recognition of foreign MHC molecules, a process termed allorecognition. This response is remarkably potent because a large fraction of the T-cell repertoire (1–10%) is alloreactive, far exceeding the frequency of T cells specific for any single microbial antigen.

Visual Explanation — Allorecognition Pathways

In the direct pathway, donor antigen-presenting cells (APCs) that travel with the graft — often dendritic cells — migrate to recipient lymph nodes and directly stimulate alloreactive T cells. Because the recipient's T-cell repertoire contains a remarkably high precursor frequency of cells that cross-react with foreign MHC molecules, the immune response is swift and vigorous. This pathway dominates in acute cellular rejection, typically occurring within the first weeks to months post-transplant.

Over time, as donor APCs are depleted from the graft and replaced by recipient APCs, the indirect pathway becomes increasingly important. Here, recipient APCs engulf shed donor MHC molecules, process them into peptide fragments, and present these fragments via self-MHC class II to recipient CD4⁺ T cells. This mechanism mirrors a conventional immune response to any exogenous protein antigen and is thought to be the principal driver of chronic rejection and transplant vasculopathy — the leading cause of late graft failure. A third, semi-direct pathway has also been described, in which recipient APCs acquire intact donor MHC via exosome transfer or cell-to-cell contact, enabling simultaneous direct and indirect presentation on a single cell.

Mechanisms of Graft Rejection

Hyperacute Rejection

Hyperacute rejection occurs within minutes to hours of transplantation and is mediated by preformed antibodies in the recipient's serum that are directed against donor endothelial antigens — typically ABO blood group antigens or HLA class I molecules. These antibodies bind the graft vasculature, activate the complement cascade, and trigger widespread thrombosis and ischemic necrosis. Histologically, the graft shows neutrophilic infiltration, fibrin deposition, and hemorrhage. Hyperacute rejection is largely prevented by ABO blood type matching and the crossmatch test (mixing recipient serum with donor lymphocytes to detect preformed anti-donor antibodies). A positive crossmatch is an absolute contraindication to transplantation.

Acute Rejection

Acute rejection typically manifests days to months after transplantation and can be subdivided into cellular (T-cell mediated) and humoral (antibody-mediated) components. In cellular acute rejection, alloreactive CD4⁺ and CD8⁺ T cells infiltrate the graft parenchyma, causing direct cytotoxicity (via perforin/granzyme and Fas/FasL pathways) and delayed-type hypersensitivity-like inflammation. Histologically, kidney biopsies show a dense mononuclear infiltrate in the tubules and interstitium — termed tubulitis. Antibody-mediated acute rejection involves de novo donor-specific antibodies (DSA) targeting donor HLA, complement fixation (C4d deposition in peritubular capillaries), and endothelial injury. Treatment typically involves pulse corticosteroids for cellular rejection, or plasmapheresis and intravenous immunoglobulin (IVIG) for antibody-mediated rejection.

Chronic Rejection

Chronic rejection develops over months to years and remains the leading cause of long-term graft loss. It is characterized by vascular intimal fibrosis (transplant vasculopathy), interstitial fibrosis, and progressive organ dysfunction. The indirect allorecognition pathway plays a central role, as do chronic antibody-mediated injury, calcineurin inhibitor nephrotoxicity, and non-immunological factors (hypertension, hyperlipidemia, diabetes). In the kidney, this manifests as chronic allograft nephropathy with tubular atrophy and interstitial fibrosis; in the lung, as bronchiolitis obliterans syndrome; and in the heart, as accelerated coronary artery disease. Chronic rejection is largely irreversible and refractory to increased immunosuppression.

Detailed Breakdown — Types of Rejection & GVHD

Worked Example — Clinical Vignette

Clinical vignettes involving transplant rejection are common on USMLE Step 1. The following worked example illustrates how to systematically approach such a question by integrating the timing, mechanism, and histological findings to reach the correct diagnosis.

Immunosuppressive Agents — Strengths & Limitations

Preventing graft rejection requires a carefully balanced immunosuppressive regimen. Most protocols employ a multi-drug approach with agents targeting different steps in the T-cell activation cascade: induction therapy at the time of transplantation, followed by maintenance therapy (typically a triple-drug regimen), and rescue therapy for acute rejection episodes. The goal is to suppress alloreactivity while minimizing the risk of opportunistic infections, malignancy, and drug-specific toxicities.

Connection to Advanced Theory — Tolerance & HLA Matching

The ultimate goal of transplantation immunology is to achieve immunological tolerance — a state in which the recipient's immune system accepts the graft without ongoing immunosuppression. Several experimental approaches are under active investigation, including mixed chimerism (infusing donor hematopoietic stem cells to create a hybrid immune system), costimulatory blockade (e.g., belatacept, which blocks the CD80/CD86–CD28 interaction), and regulatory T-cell (Treg) therapy. Understanding the three-signal model of T-cell activation is essential for appreciating how each immunosuppressive strategy targets a distinct step in the alloreactive response.

For USMLE purposes, understand the three-signal model of T-cell activation as the pharmacological framework: Signal 1 is TCR recognition of alloantigen on MHC (blocked by calcineurin inhibitors downstream). Signal 2 is costimulation (CD28–B7 interaction, blocked by belatacept). Signal 3 is cytokine-driven proliferation (IL-2 signaling through the IL-2 receptor, blocked by sirolimus/basiliximab). Without Signal 2, the T cell becomes anergic — a principle exploited in tolerance research. These concepts bridge basic immunology to both transplantation pharmacology and autoimmune disease therapy.

Practice Problems

Summary — Transplantation Immunology